scholarly journals bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer

1994 ◽  
Vol 69 (1) ◽  
pp. 135-139 ◽  
Author(s):  
Russell D Leek ◽  
Loukas Kaklamanis ◽  
Francesco Pezzella ◽  
Kevin C Gatter ◽  
Adrian L Harris
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Oestrogen Receptor ◽  
Growth Factor Receptor ◽  
Human Breast ◽  
Normal Human Breast ◽  
Normal Human ◽  
Epidermal Growth

Increased Likelihood of Mastectomy in Human Epidermal Growth Factor Receptor 2-positive Ductal Carcinoma In Situ

2014 ◽  
Vol 80 (10) ◽  
pp. 936-939 ◽  
Author(s):  
Anna Weiss ◽  
Vivi Tran ◽  
Jennifer Baker ◽  
Hasteh Farnaz ◽  
Anne M. Wallace ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Patients with human epidermal growth factor receptor 2 (HER2neu)-positive breast invasive cancer are known to have larger, more aggressive tumors. Little research exists on the relationship between HER2neu status and extent of ductal carcinoma in situ (DCIS). A retrospective review of a single-institution database was performed for patients with DCIS between the years 2002 and 2011. A single blinded breast radiologist reviewed preoperative imaging. Pathology was reviewed for extent of DCIS. Primary outcome was mastectomy. Multivariate logistic regression was used to determine adjusted mastectomy risk. There were 166 cases, 34 HER2neu-positive. HER2neu receptor-positive patients had larger lesions on imaging: 4.0 versus 2.7 cm, by 2.9 versus 1.5 cm ( P = 0.0499 and 0.0182). HER2neu-positive patients with DCIS were more likely than HER2neu-negative to undergo mastectomy than lumpectomy (53 vs 28%, P = 0.006). Pathology revealed a trend toward larger lesions in HER2neu-positive patients (2.96 vs 2.22 cm, nonsignificant). Patients with HER2neu-positive disease were three times more likely to undergo mastectomy (odds ratio, 2.9; 95% confidence interval, 1.23 to 6.78). Patients with HER2neu-positive DCIS had greater extent of disease by imaging and were more likely to undergo mastectomy than HER2neu-negative. These findings will help surgeons counsel patients on surgical treatment.

Sign in / Sign up

Export Citation Format

Share Document